|
1
|
Greer EL and Brunet A: FOXO transcription
factors at the interface between longevity and tumor suppression.
Oncogene. 24:7410–7425. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Finnberg N and El-Deiry WS: Activating
FOXO3a, NF-kappaB and p53 by targeting IKKs: An effective
multi-faceted targeting of the tumor-cell phenotype? Cancer Biol
Ther. 3:614–616. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tran H, Brunet A, Griffith EC and
Greenberg ME: The many forks in FOXO's road. Sci STKE.
2003:RE52003.PubMed/NCBI
|
|
4
|
Dijkers PF, Medema RH, Pals C, Banerji L,
Thomas NS, Lam EW, Burgering BM, Raaijmakers JA, Lammers JW,
Koenderman L and Coffer PJ: Forkhead transcription factor FKHR-L1
modulates cytokine-dependent transcriptional regulation of
p27(KIP1). Mol Cell Biol. 20:9138–9148. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schmidt M, de Fernandez Mattos S, van der
Horst A, Klompmaker R, Kops GJ, Lam EW, Burgering BM and Medema RH:
Cell cycle inhibition by FoxO forkhead transcription factors
involves downregulation of cyclin D. Mol Cell Biol. 22:7842–7852.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang JY, Xia W and Hu MC: Ionizing
radiation activates expression of FOXO3a, Fas ligand, and Bim, and
induces cell apoptosis. Int J Oncol. 29:643–648. 2006.PubMed/NCBI
|
|
7
|
Maiese K, Chong ZZ, Shang YC and Hou J:
Clever cancer strategies with FoxO transcription factors. Cell
Cycle. 7:3829–3839. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang
F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, et al: IkappaB kinase
promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell.
117:225–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang JY, Zong CS, Xia W, Yamaguchi H, Ding
Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, et al: ERK promotes
tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation.
Nat Cell Biol. 10:138–148. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
de Keizer PL, Packer LM, Szypowska AA,
Riedl-Polderman PE, van den Broek NJ, de Bruin A, Dansen TB, Marais
R, Brenkman AB and Burgering BM: Activation of forkhead box O
transcription factors by oncogenic BRAF promotes
p21cip1-dependent senescence. Cancer Res. 70:8526–8536.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang H and Tindall DJ: Dynamic FoxO
transcription factors. J Cell Sci. 120:2479–2487. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang JY and Hung MC: A new fork for
clinical application: Targeting forkhead transcription factors in
cancer. Clin Cancer Res. 15:752–757. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vogt PK, Jiang H and Aoki M: Triple layer
control: Phosphorylation, acetylation and ubiquitination of FOXO
proteins. Cell Cycle. 4:908–913. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rena G, Prescott AR, Guo S, Cohen P and
Unterman TG: Rols of the forkhead in rhabdomyosarcoma (FKHR)
phosphorylation sites in regulating 14–3-3 binding, transactivation
and nuclear targeting. Biochem J. 354:605–612. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Riquelme E, Behrens C, Lin HY, Simon G,
Papadimitrakopoulou V, Izzo J, Moran C, Kalhor N, Lee JJ, Minna JD
and Wistuba II: Modulation of EZH2 expression by MEK-ERK or
PI3K-AKT signaling in lung cancer is dictated by different KRAS
oncogene mutations. Cancer Res. 76:675–685. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Crolle G and D'Este E: Glucosamine
sulphate for the management of arthrosis: A controlled clinical
investigation. Curr Med Res Opin. 7:104–109. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Meininger CJ, Kelly KA, Li H, Haynes TE
and Wu G: Glucosamine inhibits inducible nitric oxide synthesis.
Biochem Biophys Res Commun. 279:234–239. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hua J, Sakamoto K and Nagaoka I:
Inhibitory actions of glucosamine, a therapeutic agent for
osteoarthritis, on the functions of neutrophils. J Leukoc Biol.
71:632–640. 2002.PubMed/NCBI
|
|
19
|
Ju Y, Hua J, Sakamoto K, Ogawa H and
Nagaoka I: Glucosamine, a naturally occurring amino monosaccharide
modulates LL-37-induced endothelial cell activation. Int J Mol Med.
22:657–662. 2008.PubMed/NCBI
|
|
20
|
Ju Y, Hua J, Sakamoto K, Ogawa H and
Nagaoka I: Modulation of TNF-α-induced endothelial cell activation
by glucosamine, a naturally occurring amino monosaccharide. Int J
Mol Med. 22:809–815. 2008.PubMed/NCBI
|
|
21
|
Dalirfardouei R, Karimi G and Jamialahmadi
K: Molecular mechanisms and biomedical applications of glucosamine
as a potential multifunctional therapeutic agent. Life Sci.
152:21–29. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brasky TM, Lampe JW, Slatore CG and White
E: Use of glucosamine and chondroitin and lung cancer risk in the
VITamins And Lifestyle (VITAL) cohort. Cancer Causes Control.
22:1333–1342. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hwang MS and Baek WK: Glucosamine induces
autophagic cell death through the stimulation of ER stress in human
glioma cancer cells. Biochem Biophys Res Commun. 399:111–116. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Z, Liang R, Huang GS, Piao Y, Zhang
YQ, Wang AQ, Dong BX, Feng JL, Yang GR and Guo Y: Glucosamine
sulfate-induced apoptosis in chronic myelogenous leukemia K562
cells is associated with translocation of cathepsin D and
downregulation of Bcl-xL. Apoptosis. 11:1851–1860. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oh HJ, Lee JS, Song DK, Shin DH, Jang BC,
Suh SI, Park JW, Suh MH and Baek WK: D-glucosamine inhibits
proliferation of human cancer cells through inhibition of p70S6K.
Biochem Biophis Res Commun. 360:840–845. 2007. View Article : Google Scholar
|
|
26
|
Liu BQ, Meng X, Li C, Gao YY, Li N, Niu
XF, Guan Y and Wang HQ: Glucosamine induces cell death via
proteasome inhibition in human ALVA41 prostate cancer cell. Exp Mol
Med. 43:487–493. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ju Y, Yu A, Sun X, Wu D and Zhang H:
Glucosamine, a naturally occurring amino monosaccharide, inhibits
A549 and H446 cell proliferation by blocking G1/S transition. Mol
Med Rep. 8:794–798. 2013.PubMed/NCBI
|
|
28
|
Ozcan S, Andrali SS and Cantrell JE:
Modulation of transcription factor function by O-GlcNAc
modification. Biochim Biophys Acta. 1799:353–364. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zheng Y, Jaklitsch MT and Bueno R:
Neoadjuvant therapy in non-small cell lung cancer. Surg Oncol Clin
N Am. 25:567–584. 2016. View Article : Google Scholar : PubMed/NCBI
|
